Influenza Reporter Virus Particles

Influenza Reporter Virus Particles

Integral Molecular's Influenza Reporter Virus Particles (RVPs) are replication-incompetent pseudotyped virus particles that enable safe (BSL-2), easy, and high-throughput viral infectivity and neutralization assays using standard detection instrumentation. The RVPs display hemagglutinin (HA) and neuraminidase (NA) proteins on a heterologous virus core and carry a modified genome that expresses a convenient optical reporter gene (GFP or luciferase).

Conventional hemagglutination assays require handling of live and sometimes highly pathogenic BSL-3 viruses that are subject to genetic drift upon propagation. In contrast, Influenza RVPs are available as a phenotypically stable, safe, and ready-to-use reagent.



Advantages of Influenza RVPs

- Stable HA sequence without antigenic drift
- Safe in a BSL-2 environment
- Convenient readouts
  - Luciferase
  - GFP fluorescence

Applications of Integral Molecular RVPs

- Antibody neutralization
- Serum screening
- High-throughput assays

Neutralization of influenza RVPs



Infection of HEK-293T cells with Influenza RVPs was inhibited by a neutralizing monoclonal antibody (Sino #68031-H011). A non-neutralizing control antibody did not inhibit infection.

Influenza RVPs

Influenza	Cat. No
Influenza A Virus	RVP-1201
Influenza B Virus	RVP-1301
Visit our website for the most current catalog	

Additional RVPs

Virus	Cat. No
Dengue Virus Serotypes 1-4	RVP-101, 201, 301, 401
SARS-CoV-2 (70+ variants)	RVP-701 to 775
Zika Virus	RVP-601
VSV (negative control)	RVP-1002
See our complete catalog for additional viruses	

With two decades of virology experience, Integral Molecular is the industry leader in providing RVPs for applications including antibody R&D and serum screening for vaccine clinical trials.

info@integralmolecular.com 215.966.6061 integralmolecular.com

Integral Molecular's Virology & Membrane Protein Solutions

OUR MISSION

Founded in 2001, Integral Molecular's mission is to develop and apply innovative technologies that advance therapeutic discovery against difficult protein targets including viral proteins.

WHY WORK WITH US

Deep expertise in virology is at the core of Integral Molecular's 20-year history. Our technologies and R&D services enable over 400 companies working in vaccine research and drug discovery and have been published in over 350 peer-review publications including in *Cell*, *Science*, and *Nature*.

Over the past 10 years, scientists at Integral Molecular have been on the forefront of combatting viral epidemics such as Zika, Ebola, and Chikungunya, in addition to working on dengue, HIV, RSV, Hepatitis C, Hepatitis B, Equine Encephalitis, and influenza viruses.

20+
YEARS VIROLOGY EXPERIENCE

85+
REPORTER VIRUSES & VARIANTS

TRUSTED BY
100+
VIROLOGY LABORATORIES

CONTRIBUTIONS
200+
TO VIROLOGY PUBLICATIONS



Virology
The most comprehensive catalog of Reporter Virus Particles, including SARS-CoV-2, dengue, Zika, and influenza



Epitope Mapping
Conformational, high-resolution mapping to characterize antiviral antibodies, help predict viral escape and optimize MAb cocktails



MAb Specificity Profiling
The largest array of membrane proteins for *in vitro* safety & specificity profiling of antibody-based therapeutics

Lipoparticles
Virus-like particles with high-concentration, native proteins for immunization and screening

MPS Antibody Discovery
MAbs against highly conserved, structurally complex membrane proteins delivered with >95% success

info@integralmolecular.com 215.966.6061 integralmolecular.com